Board of Directors

Noel Doheny

CEO, Epigenomics USA

Noel Doheny has over 35 years of experience in the global diagnostics market. Following a successful sales career at Gilford Instruments, he assumed increasingly significant roles within the commercial organization as the organization was acquired by Corning. These included Marketing management, Market Development and General Management in chemistry, quality control and coagulation. He assumed the lead commercial leadership role at BioStar, a VC-backed, point-of-care infectious pathogen assay company. The company was acquired by Thermo Electron, where Doheny was CEO of BioStar and led all strategic efforts for clinical chemistry and pathology for Thermo.


Doheny moved into the Molecular Diagnostic field as SVP at Qiagen for diagnostics, leading the transition from sample prep to assay products. Later he led the DX efforts at Affymetrix by completing multiple cancer assays relationships. He then became CEO of Opgen, Inc a VC genome assembly company.


Currently he is CEO of Epigenomics, Inc., a leader in blood-based screening for colon cancer, where he manages all US activities and global business development and partnership development.


He serves as a Commercial Advisor to Sequenta, a market expert for Price Waterhouse Cooper and is an industry advisor to DDN News. He received his undergraduate degrees from West Virginia University where he was Phi Beta Kappa in both chemistry and biology. He completed graduate work at Georgetown University in biochemistry and in entrepreneurship at Case Western University.


Mike Hoerres

CEO, Cernostics

Mike Hoerres brings more than 30 years of experience generating revenue and building new markets in the life sciences industry to his role as CEO of Cernostics. In his role as CEO Mike leads overall strategic direction for the company, and applies his passion for improving healthcare through genomic and proteomic technologies to the company.  Previously Mike was a Principal at Geisinger Ventures, the venture arm of Geisinger Health System, where Mike led partnering activities with life science companies focused on diagnostic development and personalized medicine. Geisinger's focus on innovation in personalized healthcare led to an investment and collaboration agreement with Cernostics in 2010. Mike has also served in a variety of sales, marketing and business development roles at Affymetrix, Incyte Genomics, Source MDx, and Stratagene (acquired by Agilent).


Mike currently serves on the Board of Directors of Pennsylvania Bio, Pennylvania's largest life science trade organization supporting the life science community through advocacy, enterprise support and collaboration, and the Pennsylvania Life Sciences Institute. Mike holds a BS in biochemistry of University of Wisconsin and a Master of Science in molecular immunology from San Diego State University.


Courtland H. Longest, MBA

Director, Precision Medicine, UPMC Enterprises

Courtland Longest is a product management and marketing executive who has spent the last decade in the Precision Medicine space.  He is currently Director of Product for Precision Medicine at UPMC Enterprises, the investment and commercialization arm of UPMC in Pittsburgh, PA.  Mr. Longest focuses on identifying new areas and companies for direct investment and strategic partnership, as well as directing internal development of new products and businesses leveraging the vast UPMC clinical expertise, patient populations, payer perspectives and the significant genomics and machine learning capabilities found within the system.  He is helping drive UPMC from being a leader in the current Precision Medicine space to leading the expansion and transformation toward the new paradigm of Precision Health.  Mr. Longest also currently serves on the Board of Directors for Cernostics, Inc., a precision medicine company based in Pittsburgh, PA.


Previously Mr. Longest served as Senior Director of Product Management and Marketing for Precision Therapeutics, Inc.  During that time, he focused on discovering, developing and commercializing Precision Medicine assets in the US market – with both technical and commercial responsibility and expertise.  These included product and market development of a live-cell chemosensitivity platform for the gynecologic cancer market, numerous molecular biomarker assays across solid cancer types, and several proprietary ‘multi-gene signatures’ predicting risk of disease recurrence and drug response in colon and lung cancers – all of which enabled oncologists to treat their patients more precisely and improve their outcomes.


Mr. Longest earned his dual B.A. in “Philosophy and Political Science” and “History and Philosophy of Science” as well as a minor in Economics from the University of Pittsburgh Honors College and graduated valedictorian and Beta Gamma Sigma from the University of Central Florida where he obtained his MBA with specialization in Technology Commercialization.


LeRoy L. Metz, II

Founding Member and President, Metz Lewis

LeRoy Metz is currently President and Member of the Executive Committee of Metz Lewis Brodman Must O'Keefe, LLC, a leading law firm headquartered in Pittsburgh, PA.  LeRoy practices tax, business, and estate planning law, and has represented numerous buyers and sellers in various corporate acquisitions, sales, and mergers.  He is also a certified public accountant, and has been listed as a top rated lawyer in mergers and acquisitions in The American Lawyer and Corporate Counsel Magazine.   LeRoy is currently a board member at Zippo Manufacturing Co., and W.R. Case and Sons Cutlery Co., Chairman of DuctMate Industries, is on the Board of Trustees of the Pittsburgh Ballet Theatre.  He received an MBA from the University of Utah, and JD from the University of Pittsburgh.


Paul Schmitt, MBA

Managing Director, Novitas Capital

Paul Schmitt has served as Managing Director of Novitas Capital in Wayne, Pennsylvania since 1999. As Managing Director, he oversees Novitas Capital's interests in early stage life sciences companies. In May of 2009, Mr. Schmitt assumed an additional role of Acting CEO of Amorcyte, a Novitas portfolio company, developing cell therapies for Cardiovascular Disease and AMI. In October 2011, Amorcyte was sold to Neostem (AMEX:NBS) for total proceeds of $18Million plus 30% of all revenues resulting from any strategic partnerships or licensing agreements.


Prior to the formation of Novitas, Mr. Schmitt spent 23 years as CEO of 4 different life science companies whose commercial businesses encompassed medical devices, biotechnology and pre-clinical and clinical drug development services. Growth in all 4 companies was achieved largely through new product development; commercialization of early stage technologies sourced from universities, corporate acquisitions, and funded corporate partnerships. During his career Mr. Schmitt has directly raised in excess of $500 Million from venture financings, IPO's and strategic partnerships.

Prior to Novitas, Mr. Schmitt was most recently Chairman, President and Chief Executive Officer of Chrysalis International Corporation (NASDAQ: CRLS). Chrysalis was formed in 1996 through the merger of DNX Corporation (NASDAQ: DNXX) and BioClin International. Chrysalis was a leading supplier of pre-clinical and clinical drug development services, including the utilization of transgenic animal science technologies to identify and validate new human genetic targets of disease emerging from worldwide genomic initiatives. With clinical and pre-clinical operating companies in 7 countries, Chrysalis' clients included over 250 biotech and pharmaceutical industry companies in 26 countries. In April 1999, Chrysalis was merged with Phoenix International, Inc. (NASDAQ: PHXI). Prior to forming Chrysalis, Mr. Schmitt joined DNX as the company's first President and Chief Executive Officer in 1988. While as CEO of DNX, Mr. Schmitt formed Nextran, a joint venture with Baxter Health Care focused on genetically engineered organ and blood substitute products. Baxter funded the joint venture with an initial $20 Million investment and subsequently acquired Nextran in 1995. Mr. Schmitt served as President of Nextran until the sale to Baxter.


Prior to joining DNX, Mr. Schmitt was President of Biolectron, Inc., which developed therapeutic devices for treating a variety of debilitating orthopedic disorders. He also has eight years experience with the BOC Health Care Group where he served as Vice President, General Manager of Ohmeda and as Corporate Manager of Strategic Planning and Corporate Group Finance Manager.


Mr. Schmitt currently serves on the Board of Trustees of the Wistar Institute and is Chairman of its Intellectual Property Committee. He serves on the Boards of Directors of 4 Novitas Capital portfolio companies: Amorcyte, Logical Therapeutics, Tetralogic Pharmaceuticals and GelMed. Mr. Schmitt received his BS in Finance at Lehigh University ('74), and his MBA from Rutgers University ('79).

Customer Service

Mon-Fri 9am-5pm (EST)